Latest Product Updates and Feature Enhancements on eMVision
EMvision Medical Devices (ASX:EMV): Portable Stroke Imaging Technology ...
EMvision is advancing its portable brain imaging technology, the emu device, through clinical validation. The company is focused on achieving FDA regulatory clearance for its device, which aims to im...prove stroke diagnosis in emergency and pre-hospital settings. The technology's success hinges on clinical trial outcomes and regulatory approval, with investors closely monitoring these developments.
EMVision Medical Devices Achieves Key Trial Enrollment Milestones ...
EMVision Medical Devices has achieved key enrollment milestones in its Pivotal Trial for the emuâ„¢ brain scanner, surpassing targets for both training and primary analysis cohorts. The company plans... to add an acute ischaemia detection endpoint, enhancing the device's clinical utility and commercial value. EMVision is also preparing for an FDA De Novo clearance submission and a new study launch in late 2026.
EMVision Making Strong Progress with emu and First Responder Brain Scanners
EMVision is advancing its emu brain scanner validation trial, achieving key recruitment milestones to support FDA De Novo clearance. The trial aims to demonstrate high sensitivity and specificity in ...hemorrhage detection. EMVision is also enhancing its First Responder portable device for pre-hospital stroke and TBI diagnosis, with multiple studies underway to validate its clinical and commercial value.
EMVision (ASX: EMV) Portable Brain Scanners Edge Closer to a Crucial US ...
EMVision is advancing the clinical validation of its portable 'emu' brain scanner towards a US FDA pathway. The device aims to speed up stroke diagnosis at the bedside and potentially in pre-hospital... settings. EMVision has reached patient recruitment milestones and is focusing on an ischaemia detection endpoint to support a De Novo clearance. The technology uses electromagnetic imaging and algorithms, distinguishing it from traditional CT or MRI scanners.
EMVision Secures Nature-Portfolio Validation for AI Stroke Scanner
EMVision's EMView study, featuring the emuâ„¢ RF brain scanner and proprietary AI models, has been published in npj Digital Medicine, part of the Nature portfolio. This peer-reviewed validation highl...ights the scanner's strong performance in differentiating stroke types, supporting EMVision's clinical and commercial efforts and bolstering its intellectual property with new patent filings.
EMV EMVision AI Stroke Detection Earns Nature Validation
EMVision's emu AI stroke detection platform has received peer-reviewed validation in the Nature-portfolio journal npj Digital Medicine. The platform demonstrated 95% sensitivity for ischaemic strokes... and 92% for haemorrhagic strokes. A new patent application was filed based on the dielectric permittivity ordering across stroke types. This validation supports EMVision's pivotal trials and enhances its intellectual property portfolio.
EMVision expands FDA trial for Ischaemia detection
EMVision Medical Devices is expanding its FDA De Novo trial to include acute ischaemia detection, enhancing the clinical utility of its portable brain-imaging device, the "emu". The trial aims to str...eamline regulatory pathways for multiple indications, with over 125 patients recruited and no device-related adverse events. Full enrolment is expected by late 2026, supported by strong cash reserves and CRC-P funding.
EMVision expands pivotal stroke scanner trial to include acute ...
EMVision is expanding its pivotal trial for a stroke scanner to include acute stroke patients. This trial aims to enhance the device's capabilities in diagnosing and managing strokes more effectively.
EMVision has announced the expansion of its pivotal stroke trial, aiming to enhance the development and validation of its innovative imaging technology for stroke diagnosis and management.
EMVision Medical Devices (ASX:EMV) Pushes Ahead with Expanded FDA ...
EMVision Medical Devices is expanding its Pivotal Trial for the emuTM Brain Scanner to include an acute ischaemia detection endpoint, aiming to enhance its FDA De Novo clearance pathway. This strateg...ic move could save time and costs by integrating ischaemia validation into the existing trial framework, potentially strengthening the device's clinical and commercial value.
Inside Biotech: EMVision pushes stroke scanner closer to broader ...
EMVision Medical Devices Ltd is advancing its emuTM point-of-care brain scanner by integrating acute ischaemic stroke detection into its FDA validation pathway. This move enhances the scanner's clini...cal utility and commercial potential. The ongoing pivotal validation trial, involving major stroke centers, aims to demonstrate high sensitivity and specificity in haemorrhage detection. EMVision's strategy could reduce validation timelines and costs, supporting broader adoption, including in pre-hospital settings.
EMVision expands pivotal emu brain scanner trial to include acute ...
EMVision is expanding its pivotal trial for the EMU brain scanner to include acute stroke patients. This trial aims to assess the scanner's effectiveness in real-world clinical settings, potentially ...enhancing stroke diagnosis and treatment.
EMVision Expands Pivotal FDA Trial to Include Acute Ischaemia Detection
EMVision is expanding its FDA De Novo trial to include acute ischaemia detection for its emu device, aiming to broaden its indications and streamline regulatory approval. The trial has recruited over... 125 patients, with full enrolment expected by late 2026/early 2027. The company holds AUD 18.4 million in cash reserves, supporting trial execution and commercialization milestones.
EMVision Medical Devices (ASX:EMV) Advances FDA Pathway with Multi-Site ...
EMVision Medical Devices is advancing its FDA approval process by expanding its pivotal trial for the emu brain scanner to eight global hospitals, including Mayo Clinic and UCLA Health. The company i...s also testing its First Responder device in pre-hospital settings. With a strong financial position bolstered by grants and tax incentives, EMVision is well-positioned for commercialization milestones.
EMVision has introduced a backpack-sized brain scanner for first responders, enabling image transmission to stroke experts from ambulances. This lightweight device, a second-generation version of the...ir existing bedside scanner, offers full brain coverage in a single scan and is set for studies to support regulatory approval.
EMVision is set to begin a pivotal trial for its portable stroke scanner, emu, aimed at obtaining US FDA approval. The trial will involve up to 300 suspected stroke patients across six sites in the U...S and Australia. EMVision's technology focuses on early stroke detection and differentiation, crucial during the 'golden hour' post-stroke. The company is transitioning from R&D to commercialization, with plans for market entry pending FDA clearance in 2026.
EMVisions stroke scanner pivotal trial gathers momentum - The Advertiser
EMVision is advancing its pivotal trial for the emu point-of-care brain scanner, with seven top stroke hospitals in the US and Australia actively enrolling patients. The trial aims to secure FDA de n...ovo clearance by demonstrating high sensitivity and specificity in hemorrhage detection. A new software feature for real-time scan feedback is in testing, enhancing product capabilities.
